FRM
PLX icon

Fore Research & Management’s Protalix BioTherapeutics PLX Stock Holding History

Fore Research & Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-11,930
Closed -$435K – 103
2014
Q2 		$435K Buy
11,930
+1,930
+19% +$77.8K 0.01% 60
2014
Q1 		$458K Sell
10,000
-13,468
-57% -$628K 0.01% 86
2013
Q4 		$913K Buy
23,468
+3,468
+17% +$146K 0.04% 56
2013
Q3 		$906K Buy
+20,000
New +$1.03M 0.06% 45

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Fore Research & Management's PLX Position: Q3 2014 in Review

Fore Research & Management sold out of Protalix BioTherapeutics (PLX) in Q3 2014, closing a stake of 11,930 shares — an estimated $435K sold.

Fore Research & Management first reported a position in PLX in Q3 2013 and held it in 4 quarters. The position peaked at $913K in Q4 2013. 43 funds tracked by Wall St. Rank hold PLX as of Q3 2014.

  • Fore Research & Management reported no remaining Protalix BioTherapeutics position as of Q3 2014 after selling out during the quarter.
  • Fore Research & Management sold 11,930 Protalix BioTherapeutics shares in Q3 2014, an estimated $435K.
  • Fore Research & Management first reported a position in Protalix BioTherapeutics in Q3 2013 and held it in 4 quarters.
  • Fore Research & Management's Protalix BioTherapeutics position peaked at $913K in Q4 2013.
  • 43 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2014.

Based on Fore Research & Management's 13F filing for Q3 2014, filed 13 Nov 2014.